How Genetic Testing Can Guide Psychiatric Medication Choices and Reduce Side Effects

Genetic testing can offer useful insight into how your body processes psychiatric medications. It doesn’t choose the “perfect” medication, but it can help guide dosing, reduce side effects, and explain past treatment challenges.

Key Points

• CYP2D6 and CYP2C19 variations strongly influence metabolism of many antidepressants and antipsychotics.

• Testing can guide dose adjustments and help reduce side effects.

• Results are most helpful for people who have struggled with medication intolerance or limited benefit from past treatments.

• Genetic results guide dosing—not medication choice alone.

How Genes Influence Medication Response

Your genes affect how quickly your body processes medications. This is why two people can take the same dose and have very different experiences.

Why metabolism matters

• Slow metabolizers: Medications break down slowly. Side effects are more likely at standard doses.

• Fast metabolizers: Medications clear quickly. Standard doses may feel ineffective.

• Normal metabolizers: Typical doses work as expected.

These differences are especially important in psychiatric treatment, where dose tolerance varies widely.

CYP2D6: One of the Most Important Metabolism Genes

CYP2D6 helps metabolize about 25% of all medications, including many antidepressants, antipsychotics, and some ADHD medications.

Medications affected

Antidepressants:

• Fluoxetine

• Paroxetine

• Venlafaxine

• Duloxetine

• Nortriptyline

Antipsychotics:

• Haloperidol

• Risperidone

• Aripiprazole

ADHD:

• Atomoxetine

Metabolism types

• Slow metabolizers: Higher medication levels, increased side effects

• Somewhat slow: Slightly higher levels than average

• Normal: Typical processing

• Fast: Lower medication levels, reduced benefit

Clinical impact

Using CYP2D6 results can help lower the risk of side effects by adjusting doses before problems develop.

CYP2C19: Key for Several Common Antidepressants

This gene plays a major role in metabolizing SSRIs.

Medications influenced

• Citalopram

• Escitalopram

• Sertraline

• Amitriptyline

How metabolism varies

• Slow metabolizers: Higher drug levels and side effects

• Fast and very fast metabolizers: Low drug levels, limited response

• Normal metabolizers: Expected response

Treatment guidance

• Slow metabolizers may need about half the usual starting dose.

• Very fast metabolizers may respond better to a different antidepressant.

Research shows that using CYP2C19 information improves treatment response for several SSRIs.

CYP1A2: Important for Specific Medications

CYP1A2 affects metabolism of:

• Clozapine

• Olanzapine

• Haloperidol

• Fluvoxamine

• Part of duloxetine

Smoking significantly increases CYP1A2 activity, often affecting dosing more than genetics.
For clozapine, both genetics and smoking status help guide safe dosing.

Other Genetic Factors With Emerging Evidence

Some genes have clinical value in specific situations:

HLA-B*5701

• Linked to severe skin reactions from carbamazepine

• Testing recommended before starting the medication in higher-risk populations

COMT

• Influences dopamine breakdown

• May affect response to some psychiatric medications, though research is evolving

SLC6A4 (serotonin transporter)

• Studied extensively

• Findings are inconsistent; not currently used for routine prescribing

UGT1A1

• May influence valproic acid metabolism

• Not routinely tested

MTHFR

• Affects folate metabolism

• Some people may benefit from methylfolate support alongside antidepressants

These genes may add context but are not primary drivers of prescribing decisions.

What Genetic Testing Can—and Cannot—Tell You

What it CAN help with

• Likely dose range for certain medications

• Risk for specific side effects

• Identifying medications that may be poorly tolerated

• Understanding past medication problems

What it CANNOT do

• Guarantee which medication will work best

• Ensure a medication will be side-effect-free

• Replace clinical judgment, monitoring, or follow-up

• Predict response for medications without genetic guidelines

Testing is most useful for people who have had significant side effects or multiple unsuccessful medication trials.

How Testing Works

How the sample is collected

• Quick cheek swab or saliva sample

• Usually done at home or in the office

Turnaround time

• Typically 1–2 weeks

Types of tests

• Single-gene tests (e.g., CYP2D6 only)

• Standard panels (multiple metabolism genes)

• Comprehensive panels (include additional variants)

Results outline your metabolizer type and any relevant medication-specific guidance.

Interpreting Your Results

Metabolizer categories

• Slow: Lower starting doses or alternative medications may be needed

• Somewhat slow: Adjustments may be helpful

• Normal: Standard dosing usually appropriate

• Fast: May require higher doses or different medications

Your doctor will combine your results with:

• Your symptom history

• Your previous medication responses

• Current medications

• Medical conditions

• Treatment goals

Genetics provide one important piece of the whole picture.

Cost and Insurance Considerations

• Typical cost ranges from $100–$500 depending on the test

• Insurance coverage varies widely

• Prior authorization is often required

• Many labs offer payment plans

• Direct-to-consumer kits exist but should still be interpreted by a clinician

Coverage is more likely when there is a history of medication intolerance or treatment resistance.

Current Limitations and Future Directions

Limitations

• Not all psychiatric medications have strong genetic evidence

• Research has historically focused on limited populations

• Medication response depends on many factors beyond genetics

• Implementation varies widely across healthcare systems

Advances underway

• Broader population studies

• Research on additional genetic pathways

• Integrated tools that combine genetics with clinical data

• More precise prediction models for treatment response

Pharmacogenomics will continue to evolve as more data becomes available.

Deciding Whether Genetic Testing Makes Sense for You

Consider testing if you have:

• Significant side effects from past medications

• Limited benefit from multiple trials

• Several medication options and want clearer direction

• Questions about why certain medications never worked well

Testing may be less helpful if:

• Current treatment is effective

• You’ve tolerated medications well in the past

• You need immediate treatment

• Your medications are not impacted by known genetic variants

Questions to discuss with your clinician

• Which medications in your plan have strong genetic evidence?

• How would the results change the treatment approach?

• Will insurance help with testing?

• What timeline should you expect for results?

If you want to explore whether genetic testing could assist with your medication plan, contact us to review your history and determine whether it may be useful for you.

This information is for educational purposes and should not replace professional medical advice. Genetic testing decisions should always be made in consultation with qualified healthcare providers.

References and Further Reading

1. Bousman, C. A., & Hopwood, M. (2016). Commercial pharmacogenetic-based decision-support tools in psychiatry. Lancet Psychiatry, 3(6), 585-590. Lancet
2. Zanger, U. M., & Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics, 138(1), 103-141. ScienceDirect
3. Hiemke, C., et al. (2018). AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2017. Psychopharmacology, 235(2), 395-461. Springer
4. Relling, M. V., & Klein, T. E. (2011). CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clinical Pharmacology & Therapeutics, 89(3), 464-467. Wiley
5. Ingelman-Sundberg, M. (2005). Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics Journal, 5(1), 6-13. Nature
6. Gaedigk, A., et al. (2017). The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clinical Pharmacology & Therapeutics, 102(6), 967-976. Wiley
7. Hicks, J. K., et al. (2017). Clinical Pharmacogenetics Implementation Consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clinical Pharmacology & Therapeutics, 102(1), 37-44. Wiley
8. Zierhut, H., et al. (2017). Clinical implementation of pharmacogenomics in psychiatry. American Journal of Psychiatry, 174(12), 1136-1137. AJP
9. Scott, S. A., et al. (2013). Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and citalopram dosing: 2013 update. Clinical Pharmacology & Therapeutics, 94(3), 317-323. Wiley
10. Hicks, J. K., et al. (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clinical Pharmacology & Therapeutics, 98(2), 127-134. Wiley
11. Rosenblat, J. D., et al. (2017). The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder. Journal of Clinical Psychopharmacology, 37(5), 588-594. LWW
12. Gunes, A., & Dahl, M. L. (2008). Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics, 9(5), 625-637. Future Medicine
13. Rajkumar, A. P., et al. (2013). Clinical pharmacogenetics of cytochrome P450-metabolized drugs in Asian populations. Clinical Pharmacology & Therapeutics, 94(4), 480-489. Wiley
14. Phillips, E. J., et al. (2018). Clinical Pharmacogenetics Implementation Consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update. Clinical Pharmacology & Therapeutics, 103(4), 574-581. Wiley
15. Bilder, R. M., et al. (2004). The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology, 29(11), 1943-1961. Nature
16. Serretti, A., & Kato, M. (2008). The serotonin transporter gene and effectiveness of SSRIs. Expert Review of Neurotherapeutics, 8(1), 111-120. Taylor & Francis
17. Bosó, M., et al. (2006). Homozygosity for the UGT1A1*28 variant increases the risk of hyperbilirubinemia in patients treated with atazanavir. AIDS, 20(11), 1554-1556. LWW
18. Gilbody, S., et al. (2007). Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. American Journal of Epidemiology, 165(1), 1-13. Oxford Academic
19. Pharmacogenomics Knowledge Base (PharmGKB). Clinical annotations and guidelines. PharmGKB
20. Popejoy, A. B., & Fullerton, S. M. (2016). Genomics is failing on diversity. Nature, 538(7624), 161-164. Nature